News Snapshot:
BEIJING (REUTERS) - CanSino Biologics Inc's single-dose Covid-19 vaccine, given at a lower dosage than that for adults, is safe and triggers an immune response in children aged 6-17, results from a small trial showed. Researchers decided to lower the dosage after a few participants developed fever and headaches graded at level 2 severity - the second-lowest of four levels. In children, the lower dose triggered higher antibody levels than the dosage approved for use in adults in China, according to the peer-reviewed finding from a mid-stage trial. The trial recruited 150 children and around 300 adults. The results also...
